Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Refractory or Unexplained Chronic Cough Clear all

Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424

View directory record Official record

Conditions: Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions: BAY1817080, Midazolam; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jan 19, 2023 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough

NCT04562155

View directory record Official record

Conditions: Refractory and/or Unexplained Chronic Cough
Interventions: BAY1817080, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Los Angeles, California • Largo, Florida • White Marsh, Maryland + 5 more

Source: ClinicalTrials.gov public record

Updated Aug 17, 2022 · Synced May 21, 2026, 10:13 PM EDT

Terminated Phase 2 Interventional Results available

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

NCT03979638

View directory record Official record

Conditions: Chronic Refractory Cough
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: San Diego, California • San Jose, California • Largo, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated Aug 2, 2021 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 2 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446

View directory record Official record

Conditions: Refractory or Unexplained Chronic Cough
Interventions: NOC-110, Placebo; Drug · Other
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 68
States / cities: Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more

Source: ClinicalTrials.gov public record

Updated Feb 16, 2026 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

NCT04471337

View directory record Official record

Conditions: Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions: BAY1817080; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Mar 25, 2024 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Not applicable Interventional

Cough Management Wellness App for Refractory or Unexplained Chronic Cough

NCT07070895

View directory record Official record

Conditions: Refractory Chronic Cough, Unexplained Chronic Cough, Cough Hypersensitivity
Interventions: Cough Management, CoughMonitor Suite; Behavioral · Device
Lead sponsor: Hyfe Inc; Other
Eligibility: 21 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Wilmington, Delaware

Source: ClinicalTrials.gov public record

Updated Sep 10, 2025 · Synced May 21, 2026, 10:13 PM EDT